Science Explorer Back to mapMap
Discussion
Researcher · BioInvent (Sweden) · Sweden

Petra Holmkvist

Petra Holmkvist publishes mostly in Immunology, Oncology and Radiology, Nuclear Medicine and Imaging, on topics such as Monoclonal and Polyclonal Antibodies Research, Immunotherapy and Immune Responses and Cancer Immunotherapy and Biomarkers.

ORCID 0000-0002-5324-5170 OpenAlex
World rank
#4,369,317
of 7,710,434 ranked researchers
Rank in Sweden
#52,218
of 71,437
Works
37
Citations
183
Citations per work
4.9
h-index
6
i10-index 4Top 93% in Immunology
Petra Holmkvist

What does Petra Holmkvist research?

Petra Holmkvist's work is mostly in Medicine (40%), Immunology and Microbiology (40%), Biochemistry, Genetics and Molecular Biology (5%).

Life Sciences: 18 works · 47.5% of their workImmunology and Microbiology: 15 works · 39.7% of their workImmunology: 15 works · 39.7% of their workBiochemistry, Genetics and Molecular Biology: 2 works · 5.2% of their workGenetics: 1 works · 2.6% of their workMolecular Biology: 1 works · 2.6% of their workPharmacology, Toxicology and Pharmaceutics: 1 works · 2.6% of their workPharmaceutical Science: 1 works · 2.6% of their workHealth Sciences: 15 works · 39.8% of their workMedicine: 15 works · 39.8% of their workOncology: 9 works · 23.1% of their workRadiology, Nuclear Medicine and Imaging: 6 works · 16.7% of their workEverything else: 5 works · 12.7% of their workTHEIR WORKPetra Holmkvist37works
Life Sciences48%Health Sciences40%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Immunology and Microbiology1539.7%
    2. Biochemistry, Genetics and Molecular Biology25.2%
    3. Pharmacology, Toxicology and Pharmaceutics12.6%
    1. Medicine1539.8%
  3. Everything else512.7%
  1. 1Immunology40% of their works
  2. 2Oncology23% of their works
  3. 3Radiology, Nuclear Medicine and Imaging17% of their works
  4. 4Pharmaceutical Science3% of their works
  5. 5Molecular Biology3% of their works
  6. 6Genetics3% of their works

Research topics

Which keywords describe Petra Holmkvist's research?

The keywords of their largest research topics: Cancer Immunotherapy, Fc Receptors, Therapeutic Antibodies, Dendritic Cells, Immune Checkpoint Blockade, Immunity, PD-1 and PD-L1 and CAR T Cells.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 17 words, with their numbers
  1. Cancer Immunotherapy162 topics
  2. Fc Receptors121 topic
  3. Therapeutic Antibodies121 topic
  4. Dendritic Cells101 topic
  5. Immune Checkpoint Blockade101 topic
  6. Immunity101 topic
  7. PD-1 and PD-L1101 topic
  8. CAR T Cells61 topic
  9. Chimeric Antigen Receptor61 topic
  10. Foxp361 topic
  11. NK Cell Recognition61 topic
  12. Natural Killer Cells61 topic
  13. TGF-ß61 topic
  14. IL-3331 topic
  15. Innate Lymphoid Cells31 topic
  16. Gene Therapy21 topic
  17. Viral Vectors21 topic

Where does Petra Holmkvist work?

Petra Holmkvist's main affiliation in the publication record is BioInvent (Sweden), Sweden.

How many publications and citations does Petra Holmkvist have?

OpenAlex counts 37 works and 183 citations for Petra Holmkvist, an h-index of 6, ranking #4,369,317 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Petra Holmkvist. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.